Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | KLK7 | P49862 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3468425 | 0.78 | TDP1 (0.46) | CCR2TDP1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL214431 | 0.78 | TDP1 (0.46) | CCR2TDP1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL2007672 | 0.78 | ALDH1A1 (0.48) | CCR2TDP1ALDH1A1MAPTPKM | |
| Hydrochloric Acid SCHEMBL11049903 | 0.76 | TDP1 (0.43) | CCR2TDP1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL11050586 | 0.76 | TDP1 (0.43) | CCR2TDP1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL11050566 | 0.76 | TDP1 (0.43) | CCR2TDP1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL13908191 | 0.75 | TDP1 (0.42) | CCR2TDP1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL31748021 | 0.75 | TDP1 (0.42) | CCR2TDP1L3MBTL1ALDH1A1MAPT | |
| Cimlanod SCHEMBL15878610 | 0.73 | CA1 (0.45) | CCR2TDP1L3MBTL1ALDH1A1POLB | |
| SCHEMBL15249006 | 0.72 | TLR9 (0.62) | L3MBTL1ALDH1A1MAPTPOLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210145824-A1 | MODULATORS OF CELLULAR ADHESION | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2021-05-20 | — | — | US | disclosed |
| US-20160074381-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-9216174-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140066476-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-8163918-B2 | Azaindazole compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-24 | — | — | US | disclosed |
| US-20120035370-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
| US-7879873-B2 | Azaindazole compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-2009054914-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | SARCODE CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145824-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | CCR2 337/4885TDP1 2771/4885L3MBTL1 1091/4885 |
| US-20140066476-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | CCR2 337/4885TDP1 2771/4885L3MBTL1 1091/4885 |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | CCR2 10/4885TDP1 1686/4885L3MBTL1 4281/4885 |
| US-20160074381-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | CCR2 337/4885TDP1 2771/4885L3MBTL1 1091/4885 |
| US-20120035370-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | CCR2 9/4885TDP1 1736/4885L3MBTL1 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.